PHILADELPHIA – Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn’s Perelman School of Medicine will give several high-profile presentations at the American Society for Radiation Oncology's (ASTRO) 68th Annual Meeting , taking place Sept. 26-30 in Boston.
At the meeting, Neha Vapiwala, MD, FACR, FASTRO, FASCO , the Eli J. Glatstein Professor in Radiation Oncology, will address attendees as president of ASTRO . She is the first Penn faculty member to lead the premier society for radiation oncology professionals and recently shared her insights for advancing a medical career at any stage —from applying to medical school to professional development.
Visit the Penn Radiation Medicine Institute (PRMI) at Booth #1722 and the University of Pennsylvania Radiation Oncology Education Programs at Booth #1759. Follow Penn MD Forum on X and Instagram , and the Department of Radiation Oncology on LinkedIn and Instagram for updates from the meeting.
Dozens of Penn trainees and faculty members will participate in the meeting by presenting their research and moderating scientific, educational and workshop sessions. Additionally, James Metz, MD , chair of Radiation Oncology, will moderate the second Keynote Address with former FDA Commissioner Scott Gottlieb, MD, on Tuesday, Sept. 29. Penn presentation highlights include:
Keynote Address
Ezekiel Emanuel, MD, PhD , Vice Provost for Global Initiatives at the University of Pennsylvania, will deliver the first keynote session, sharing his perspective in relation to the 2026 meeting theme: "Data to Dialogue: Communicating Radiotherapy's Value to Advance Care."
Presidential Address
Neha Vapiwala, MD, FACR, FASTRO, FASCO , the Eli J. Glatstein Professor in Radiation Oncology, will share priorities and insights from ASTRO leadership to advance the value and perceptions of radiotherapy’s role in clinical care, and to address challenges and opportunities for strengthening professional development and patient outcomes.
Scientific Session (SS27)
Michelle Alonso-Basanta, MD, PhD , professor of Radiation Oncology and chief of the Central Nervous System Service, is presenting on “Advances in Multimodal Therapy for Glioblastoma: From Phase I to Phase III Trials.” She is also co-moderator of the session and was recently named to the 2026 Class of ASTRO Fellows .
Experts from the Perelman School of Medicine are available to comment on a wide range of topics in radiation oncology care and research during the meeting on site and by video, phone, or email. To arrange interviews, please contact Meagan Raeke at Meagan.Raeke@pennmedicine.upenn.edu or 267-693-6224.
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine , founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.